Citigroup
LABP

Citigroup’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Citigroup’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-52
Closed -$260 – 6000
2022
Q4 		$260 Buy
52
+2
+4% +$8 ﹤0.01% 5575
2022
Q3 		$0 Sell
50
-24
-32% -$208 ﹤0.01% 6546
2022
Q2 		$1K Sell
74
-207
-74% -$1.88K ﹤0.01% 6148
2022
Q1 		$4K Buy
281
+36
+15% +$916 ﹤0.01% 5927
2021
Q4 		$12K Buy
245
+190
+345% +$20K ﹤0.01% 5535
2021
Q3 		$8K Buy
55
+24
+77% +$3.12K ﹤0.01% 5534
2021
Q2 		$4K Sell
31
-11
-26% -$1.23K ﹤0.01% 5891
2021
Q1 		$4K Buy
+42
New +$5.48K ﹤0.01% 5970

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup's LABP Position: Q1 2023 in Review

Citigroup sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q1 2023, closing a stake of 52 shares — an estimated $260 sold.

Citigroup first reported a position in LABP in Q1 2021 and held it in 8 quarters. The position peaked at $12K in Q4 2021. 20 funds tracked by Wall St. Rank hold LABP as of Q1 2023.

  • Citigroup reported no remaining Landos Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 52 Landos Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $260.
  • Citigroup first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
  • Citigroup's Landos Biopharma, Inc. Common Stock position peaked at $12K in Q4 2021.
  • 20 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.